Posted by Michael Wonder on 26 Jul 2017
NICE approval for nivolumab provides new treatment for advanced blood cancer
26 July 2017 - People with an advanced type of blood cancer will benefit from nivolumab on the NHS following approval by NICE.
Nivolumab, also known as Opdivo, will be routinely available for patients with classical Hodgkin lymphoma who have exhausted all other treatments.
Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: “These patients with Hodgkin lymphoma often have a poor prognosis with limited options left. Nivolumab offers them a promising treatment and our committee were able to recommend the drug as a cost effective use of NHS resources.”
